January 3, 2018 / 9:23 PM / a year ago

BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018

Jan 3 (Reuters) - Dova Pharmaceuticals Inc:

* DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

* DOVA PHARMACEUTICALS INC - SUPPLEMENTAL NDA FOR ITP TO BE SUBMITTED IN SECOND HALF OF 2018

* DOVA PHARMACEUTICALS INC - PHASE 3 CLINICAL TRIAL FOR CIT TO BEGIN IN Q2 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below